Colaci Carmen, Mercuri Caterina, Corea Alessandro, Spagnuolo Rocco, Doldo Patrizia
Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.
Department of Clinical and Experimental Medicine, University "Magna Graecia", 88100 Catanzaro, Italy.
Life (Basel). 2025 Mar 7;15(3):421. doi: 10.3390/life15030421.
Neuroendocrine tumors (NETs) of the liver are a rare entity. NETs are often poorly recognized, with diagnostic difficulties and differential challenges between primary tumors of the liver and metastases from other organs, mainly from the gastrointestinal tract. Multidisciplinary and multi-technical diagnosis is mandatory to properly treat these tumors. This case describes the complex history and the treatment course of a 68-year-old man with a history of NET onset after liver transplantation. Liver transplantation is the treatment of choice for patients with advanced liver disease or acute liver failure, but careful pre- and post-transplant patient monitoring is required. Liver transplant patients receive immunosuppressive therapy, and donor livers should be screened to exclude potential malignancies. This clinical case, in addition to emphasizing the diagnostic and therapeutic difficulty of hepatic NET, underlines the role of post-transplant immunosuppressive therapy and pre-transplant screening, which includes a thorough evaluation of donor and recipient history, physical examination, and laboratory tests. Moreover, post-transplant immunosuppressive therapy is essential to maintain the viability of the transplanted organ, but it is not free from potential risks, including an increased risk of cancer. Therefore, close monitoring of therapy is necessary to optimize long-term results and the patient's quality of life.
肝脏神经内分泌肿瘤(NETs)是一种罕见的疾病。NETs常常难以识别,在肝脏原发性肿瘤与其他器官(主要是胃肠道)转移瘤之间存在诊断困难和鉴别挑战。多学科和多技术诊断对于正确治疗这些肿瘤至关重要。本病例描述了一名68岁男性在肝移植后发生NET的复杂病史和治疗过程。肝移植是晚期肝病或急性肝衰竭患者的首选治疗方法,但移植前后需要对患者进行仔细监测。肝移植患者接受免疫抑制治疗,应对供肝进行筛查以排除潜在恶性肿瘤。本临床病例除了强调肝脏NET的诊断和治疗难度外,还突出了移植后免疫抑制治疗和移植前筛查的作用,其中包括对供体和受体病史、体格检查及实验室检查的全面评估。此外,移植后免疫抑制治疗对于维持移植器官的存活至关重要,但并非没有潜在风险,包括癌症风险增加。因此,密切监测治疗对于优化长期疗效和患者生活质量是必要的。